Biotech, Cannabis, Food & Drug, & Pharma Law Updates

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotech, Cannabis, Food & Drug, & Pharma Administration News

Title
Publication Date Organization
Dec
18
2023
The ‘One Substance, One Assessment Package’: Implications, Upcoming Pilot Project, Impact on EFSA Keller and Heckman LLP
Dec
15
2023
November 2023 Bounty Hunter Plaintiff Claims Keller and Heckman LLP
Dec
15
2023
Cell-Cultivated Meats: Nutrition, Safety, and Global Growth Womble Bond Dickinson (US) LLP
Dec
15
2023
FDA Proposes Reorganization for HFP and ORA Keller and Heckman LLP
Dec
15
2023
Unable to Individually Trace PFAS to Manufacturers, Sixth Circuit Dismisses PFAS Class Action Foley & Lardner LLP
Dec
14
2023
President Seeks More Antitrust Scrutiny of Health Care Transactions Epstein Becker & Green, P.C.
Dec
14
2023
If the Label Is Skinny Enough – No Inducement Under Hatch-Waxman McDermott Will & Emery
Dec
14
2023
EPA’s Proposed Registration of a Sprayable RNAi Biopesticide — A Conversation with Meibao Zhuang, Ph.D. [Podcast] Bergeson & Campbell, P.C.
Dec
14
2023
ECHA Calls for Evidence on Certain Chromium (VI) Substances Bergeson & Campbell, P.C.
Dec
13
2023
Federal Circuit Evaluates Impact of the Final Written Decision (FWD) in a Parallel Inter-Partes Review (IPR) on District Court’s decision of Invalidity and Infringement Sheppard, Mullin, Richter & Hampton LLP
Dec
13
2023
AMCC Awards Five Integrated Licenses, Chaos to Follow Bradley Arant Boult Cummings LLP
Dec
13
2023
FDA Announces Draft Supplemental Guidance on Menu Labeling Keller and Heckman LLP
Dec
13
2023
M&A Primer for Emerging Healthy F&B Companies Foley & Lardner LLP
Dec
12
2023
US House Introduces Bipartisan Feed Ingredient Bill Keller and Heckman LLP
Dec
12
2023
Korea Introduces More Rules to Enhance Oversight of Alternative Protein Foods Keller and Heckman LLP
Dec
11
2023
The March on Pharmaceutical Patents? Sheppard, Mullin, Richter & Hampton LLP
Dec
8
2023
EC Committee Begins Public Consultation on Its Preliminary Opinion for Titanium Dioxide Bergeson & Campbell, P.C.
Dec
8
2023
FDA Approves Two Gene Therapies to Treat Sickle Cell Disease Including a CRISPR-Based Therapy Foley & Lardner LLP
Dec
8
2023
McDermottPlus Check-Up: December 8, 2023 McDermott Will & Emery
Dec
8
2023
China on the Move: Fine-Tuning the Life Sciences Regulatory and Compliance Landscape Greenberg Traurig, LLP
Dec
8
2023
Prolific Plaintiff’s Lawyer Held in Contempt Keller and Heckman LLP
Dec
8
2023
Hospital Executive and Three Physicians to Pay More Than $880,000 to Resolve Kickback Allegations ArentFox Schiff LLP
Dec
8
2023
Illinois Supreme Court: Finger-Scan Information Collected by Healthcare Providers to Access Medications Is Exempt From BIPA Liability McDermott Will & Emery
Dec
7
2023
Win for Healthcare Institutions: Illinois High Court Rules Healthcare Employees’ Biometrics Exempt from BIPA Requirements Squire Patton Boggs (US) LLP
Dec
7
2023
Total Wine Tests the Boundaries of FTC CIDs McDermott Will & Emery
Dec
7
2023
Missouri Bill Proposed to Preempt California’s Proposition 12 Keller and Heckman LLP
Dec
6
2023
White House OSTP and NNCO Announce Series of Events in Celebration of 20th Anniversary of the Authorization of the NNI Bergeson & Campbell, P.C.
Dec
6
2023
Decentralized Clinical Trials: Diversity in Clinical Trials Foley & Lardner LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins